189 related articles for article (PubMed ID: 18571837)
1. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.
Tischkowitz MD; Yilmaz A; Chen LQ; Karyadi DM; Novak D; Kirchhoff T; Hamel N; Tavtigian SV; Kolb S; Bismar TA; Aloyz R; Nelson PS; Hood L; Narod SA; White KA; Ostrander EA; Isaacs WB; Offit K; Cooney KA; Stanford JL; Foulkes WD
Cancer Lett; 2008 Oct; 270(1):173-80. PubMed ID: 18571837
[TBL] [Abstract][Full Text] [Related]
2. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
3. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
Shaag A; Walsh T; Renbaum P; Kirchhoff T; Nafa K; Shiovitz S; Mandell JB; Welcsh P; Lee MK; Ellis N; Offit K; Levy-Lahad E; King MC
Hum Mol Genet; 2005 Feb; 14(4):555-63. PubMed ID: 15649950
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant.
Laitman Y; Nielsen SM; Hatchell KE; Truty R; Bernstein-Molho R; Esplin ED; Friedman E
Fam Cancer; 2022 Jul; 21(3):305-308. PubMed ID: 34622392
[TBL] [Abstract][Full Text] [Related]
5. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD
BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Clinical and Genetic Analysis of
Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
[TBL] [Abstract][Full Text] [Related]
9. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
10. Mutations in CHEK2 associated with prostate cancer risk.
Dong X; Wang L; Taniguchi K; Wang X; Cunningham JM; McDonnell SK; Qian C; Marks AF; Slager SL; Peterson BJ; Smith DI; Cheville JC; Blute ML; Jacobsen SJ; Schaid DJ; Tindall DJ; Thibodeau SN; Liu W
Am J Hum Genet; 2003 Feb; 72(2):270-80. PubMed ID: 12533788
[TBL] [Abstract][Full Text] [Related]
11. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
[TBL] [Abstract][Full Text] [Related]
12. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
13. Genetic architecture of prostate cancer in the Ashkenazi Jewish population.
Vijai J; Kirchhoff T; Gallagher D; Hamel N; Guha S; Darvasi A; Lencz T; Foulkes WD; Offit K; Klein RJ
Br J Cancer; 2011 Sep; 105(6):864-9. PubMed ID: 21829199
[TBL] [Abstract][Full Text] [Related]
14. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.
Rennert H; Bercovich D; Hubert A; Abeliovich D; Rozovsky U; Bar-Shira A; Soloviov S; Schreiber L; Matzkin H; Rennert G; Kadouri L; Peretz T; Yaron Y; Orr-Urtreger A
Am J Hum Genet; 2002 Oct; 71(4):981-4. PubMed ID: 12145743
[TBL] [Abstract][Full Text] [Related]
15. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
[TBL] [Abstract][Full Text] [Related]
16. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CHEK2 mutations in prostate cancer.
Wu X; Dong X; Liu W; Chen J
Hum Mutat; 2006 Aug; 27(8):742-7. PubMed ID: 16835864
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.
Delimitsou A; Fostira F; Kalfakakou D; Apostolou P; Konstantopoulou I; Kroupis C; Papavassiliou AG; Kleibl Z; Stratikos E; Voutsinas GE; Yannoukakos D
Hum Mutat; 2019 May; 40(5):631-648. PubMed ID: 30851065
[TBL] [Abstract][Full Text] [Related]
19. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
[TBL] [Abstract][Full Text] [Related]
20. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N;
Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
